Valneva shares rise 3.95% premarket after EMA lifted restriction on chikungunya vaccine for the elderly.

Valneva Se surged 3.95% in premarket trading, following the European Medicines Agency (EMA) lifting its temporary restriction on the company's chikungunya vaccine for the elderly. The EMA's decision to remove the restriction on vaccinating individuals aged 65 and over with its single-dose chikungunya vaccine, Ixchiq, after a comprehensive review, has positively impacted the company's stock performance.